A New Target in Advanced Cancer Treatment: The DNA Repair Mechanism

In a new paper from the United Kingdom published in Cancer Discovery on 28 September 2020, scientists reported that cancer cells' DNA repair process was blocked by a new precision drug that showed promise in an early-stage clinical trial (a human study).
The researchers reported that the drug used in the trials belonged to the group known as ATR inhibitors, which stop the activity of the ATR enzyme involved in DNA repair, and that the results highlighted the importance of this drug group.
For the first time, this drug candidate with therapeutic potential was tested in humans and shown to be well tolerated by patients and to stop tumor growth in more than half of them.
Details of the cancer treatment trial with ATR inhibitors
The study included previously treated patients with advanced breast, colon (large intestine), and prostate cancer, for a total of 21 patients. Among patients with differences in their genes involved in DNA repair, 11 had deletion mutations or other differences affecting the ATM gene. The team conducting the study emphasized that the new drug's phase 1 trial results in patients with advanced disease were extremely promising and encouraging for later-phase studies.
The study aimed to determine the safety and maximum tolerated dose of the ATR-inhibiting agent (BAY1895344), produced by Bayer, in cancer patients who had previously received many drug treatments. Researchers found that the drug showed activity against cancer in patients with defects affecting ATM gene activity and was well tolerated by patients.
The study's lead researcher summarizes the results and their importance in these words: “In tumors with impaired DNA damage responses, DNA replication stress responses, and activation defects in ATM signaling, the drug targeting the ATR enzyme shows anticancer activity. The highest dose tolerable to patients was established, and the most common side effects were manageable and reversible hematological toxicities. The trials found 4 patients with a partial response and 8 patients with stable disease, while the median response duration was found to be 315.5 days. The responses obtained from patients in early-stage clinical studies are promising and also excite us about later-stage clinical trials. One of our future goals is to find new treatment targets and test drugs in combination, thereby overcoming cancer patients' drug treatment resistance that develops ”.
Summary and conclusion
The ATR-inhibiting agent developed by the pharmaceutical company showed effective antitumor properties in patients with impaired DNA damage responses and without an ATM gene. The team analyzing its biochemical and pharmacological effects also found that the drug acts by increasing DNA damage. The new findings highlight the importance of focusing on treatment strategies targeting the ATR protein involved in repair, particularly in patients with specific defects in DNA repair genes such as ATM or BRCA1, because correcting DNA repair is difficult. This new anticancer agent is very similar to PARP inhibitors in targeting DNA repair.
In contrast to chemotherapy drugs with a general mechanism of action, developing more target-directed treatment methods increases treatment responses and offers hope to cancer patients.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.